The company specializes in researching diagnostic biomarkers and uses drug screening and genome big data analysis to develop drugs that target specific proteins associated with tumor metastasis, therapy resistance, and immune evasion. Their approach aims to inhibit the enzymatic activity of these proteins, allowing hospitals to implement more successful cancer treatments. Founded in 2019 and based in Seoul, South Korea, Checkmate Therapeutics focuses on discovering and developing novel approaches for cancer immunotherapy, particularly in the field of immuno-oncology.